CoChat
Sign Up
Cited by 34Bacterial Infections and VaccinesHealth Systems, Economic Evaluations, Quality of LifePneumonia and Respiratory Infections

The DOI matches its Crossref record, with a small difference in title or year; 2 of the 2 references it cites were found in a registry or an index.

Estimating costs of care for meningitis infections in low- and middle-income countries

Portnoy, Allison, Jit, Mark, Lauer, Jeremy, Blommaert, Adriaan, Ozawa, Sachiko, Stack, Meghan, Murray, Jillian, Hutubessy, Raymond·2015·Vaccine
DOI 10.1016/j.vaccine.2014.11.061
Open this paper in CoChat — free account

Abstract

Meningitis infections are often associated with high mortality and risk of sequelae. The costs of treatment and care for meningitis are a great burden on health care systems, particularly in resource-limited settings. The objective of this study is to review data on the costs of care for meningitis in low- and middle-income countries, as well as to show how results could be extrapolated to countries without sound data. We conducted a systematic review of the literature from six databases to identify studies examining the cost of care in low- and middle-income countries for all age groups with suspected, probable, or confirmed meningitis. We extracted data on treatment costs and sequelae by infectious agent and/or pathogen, where possible. Using multiple regression analysis, a relationship between hospital costs and associated determinants was investigated in order to predict costs in countries with missing data. This relationship was used to predict treatment costs for all 144 low- and middle-income countries. The methodology of conducting a systematic review, extrapolating, and setting up a standard database can be used as a tool to inform cost-effectiveness analyses in situations where cost of care data are poor. Both acute and long-term costs of meningitis could be extrapolated to countries without reliable data. Although only bacterial causes of meningitis can be vaccine-preventable, a better understanding of the treatment costs for meningitis is crucial for low- and midd…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.vaccine.2014.11.061

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 85

  1. Vos, 2012, Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010, Lancet, 380, 2163, 10.1016/S0140-6736(12)61729-2 · DOI · Paper page
  2. Ayieko, 2009, The economic burden of inpatient paediatric care in Kenya: household and provider costs for treatment of pneumonia, malaria and meningitis, Cost Eff Resour Alloc, 7, 3, 10.1186/1478-7547-7-3 · DOI
  3. Rajasingham, 2012, Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis, PLoS Med, 9, e1001316, 10.1371/journal.pmed.1001316 · DOI
  4. Carey, 2011, Controlling for quality in the hospital cost function, Health Care Manag Sci, 14, 125, 10.1007/s10729-010-9142-7 · DOI
  5. Granneman, 1986, Estimating hospital costs, J Health Econ, 5, 107, 10.1016/0167-6296(86)90001-9 · DOI
  6. O’Neill, 1997, Issues in cost function specification for neonatal care: the Fordham case, J Public Health Med, 19, 50, 10.1093/oxfordjournals.pubmed.a024587 · DOI
  7. Adam, 2008, Capacity utilization and the cost of primary care visits: implications for the costs of scaling up health interventions, Cost Eff Resour Alloc, 6, 22, 10.1186/1478-7547-6-22 · DOI
  8. Adam, 2006, Determinants of variation in the cost of inpatient stays versus outpatient visits in hospitals: a multi-country analysis, Soc Sci Med, 63, 1700, 10.1016/j.socscimed.2006.04.023 · DOI
  9. Adam, 2003, Econometric estimation of country-specific hospital costs, Cost Effectiveness Resour Allocation, 1, 3, 10.1186/1478-7547-1-3 · DOI
  10. Tiku, 1971, Power function of the F-test under non-normal situations, J Am Stat Assoc, 66, 913
  11. Akaike, 1974, A new look at the statistical model identification, IEEE Trans Autom Control, 19, 716, 10.1109/TAC.1974.1100705 · DOI · Paper page
  12. Duan, 1983, Smearing estimate: a nonparametric retransformation method, J Am Stat Assoc, 78, 605, 10.1080/01621459.1983.10478017 · DOI
  13. Alvis Guzmán, 2006, The cost-effectiveness of Haemophilus influenzae type b vaccine for children under 2 years of age in Colombia, Rev Panam Salud Publica/Pan Am J Public Health, 20, 248
  14. Arciniegas, 2006, Extrapulmonary tuberculosis: a review of 102 cases in Pereira, Colombia, Biomédica, 26, 71, 10.7705/biomedica.v26i1.1396 · DOI
  15. Chicaíza-Becerra, 2007, Economic impact of pneumococcal vaccine on oncological patients, Rev Salud Publica, 9, 342, 10.1590/S0124-00642007000300003 · DOI
  16. Larraz, 2010, Cost-effectiveness of universal pneumococcal vaccination in Uruguay, Rev Panam Salud Publica/Pan Am J Public Health, 28, 92
  17. Lucarevschi, 2012, Hospital costs related to streptococcal meningitis among children in Sao Jose dos Campos, Sao Paulo State, Brazil, Cad Saúde Pública (Rio de Janeiro), 28, 740, 10.1590/S0102-311X2012000400013 · DOI
  18. Soltani, 2005, Epidemiology of Haemophilus influenzae b meningitis in Tunisia, La Revue de Santé de la Méditerranée orientale, 11, 14
  19. Stoicescu, 2007, Preliminary assessment of Streptococcus pneumoniae, pneumonia, economical and clinical burden in Romania, Pneumologia (Bucharest, Romania), 56, 118
  20. Akpede, 1999, Response to antimicrobial therapy in childhood bacterial meningitis in tropical Africa: report of a bi-centre experience in Nigeria, 1993–1998, Ann Trop Paediatr, 19, 237, 10.1080/02724939992301 · DOI
  21. Al-Howasi, 1996, The use of a modified out-patient infusion therapy for lowering the cost in suleimania child's hospital, J Kuwait Med Assoc, 28, 455
  22. Cullinan, 1998, Packaged treatment for first-line care in cerebral malaria and meningitis, Bull World Health Organ, 76, 257
  23. Giglio, 2010, Cost-effectiveness of the CRM-based 7-valent pneumococcal conjugated vaccine (PCV7) in Argentina, Vaccine, 28, 2302, 10.1016/j.vaccine.2009.12.070 · DOI
  24. Whittle, 1973, Trial of chloramphenicol for meningitis in northern savanna of Africa, Br Med J, 3, 379, 10.1136/bmj.3.5876.379 · DOI
  25. McNeil, 1980, Cost effectiveness calculations for the diagnosis and treatment of tuberculous meningitis, Eur J Nucl Med, 5, 271, 10.1007/BF00271911 · DOI
  26. Meya, 2010, Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or =100 cells/microL who start HIV therapy in resource-limited settings, Clin Infect Dis, 51, 448, 10.1086/655143 · DOI
  27. Muangchana, 2011, Incorporation of private demand into cost-benefit analysis of a universal Hib vaccination program in Thailand, Southeast Asian J Trop Med Public Health, 42, 376
  28. Shillcutt, 2013, Forecasting burden of long-term disability from neonatal conditions: results from the Projahnmo I trial, Sylhet, Bangladesh, Health Policy Plan, 28, 435, 10.1093/heapol/czs075 · DOI
  29. Sinha, 2007, Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis, Lancet, 369, 389, 10.1016/S0140-6736(07)60195-0 · DOI
  30. Tate, 2011, Projected health benefits and costs of pneumococcal and rotavirus vaccination in Uganda, Vaccine, 29, 3329, 10.1016/j.vaccine.2010.12.122 · DOI
  31. Uruena, 2011, Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina, Vaccine, 29, 4963, 10.1016/j.vaccine.2011.04.111 · DOI
  32. Wone, 1976, Contribution to the study of cerebro-spinal meningitis in Niger, Bulletin de la Societe Medicale d’Afrique Noire de Langue Francaise, 21, 395
  33. Wongsawat, 2010, Implication of pneumococcal conjugate vaccines to public health: Thailand perspective, J Med Assoc Thai, 93, S53
  34. Adoga, 2010, Chronic suppurative otitis media: socio-economic implications in a tertiary hospital in Northern Nigeria, Pan Afr Med J, 4, 3, 10.4314/pamj.v4i1.53613 · DOI
  35. Hussain, 2008, Economic analysis of childhood pneumonia in Northern Pakistan, Health Policy Plan, 23, 438, 10.1093/heapol/czn033 · DOI
  36. Isturiz, 2010, Clinical and economic burden of pneumonia among adults in Latin America, Int J Infect Dis, 14, e852, 10.1016/j.ijid.2010.02.2262 · DOI
  37. Da Silva, 2003, Microeconomic evaluation of a mass preventive immunisation campaign against meningococcal meningitis and yellow fever in Senegal in 1997, Cahiers Sante, 13, 215
  38. Hegde, 2005, Post-marketing study to assess the safety, tolerability and effectiveness of Fungisome(trademark): An Indian liposomal amphotericin B preparation, J Postgrad Med, 51, 58
  39. Miller, 1999, Evaluation of meningococcal meningitis vaccination strategies for the meningitis belt in Africa, Pediatr Infect Dis J, 18, 1051, 10.1097/00006454-199912000-00005 · DOI
  40. Parasuraman, 2001, Enteroviral meningitis: cost of illness and considerations for the economic evaluation of potential therapies, Pharmacoeconomics, 19, 3, 10.2165/00019053-200119010-00001 · DOI
  41. Parent du Chatelet, 2001, Comparison of cost-effectiveness of preventive and reactive mass immunization campaigns against meningococcal meningitis in West Africa: a theoretical modeling analysis, Vaccine, 19, 3420, 10.1016/S0264-410X(01)00066-4 · DOI
  42. Sohn, 2010, Economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Korea, J Manag Care Pharm, 16, 32, 10.18553/jmcp.2010.16.1.32 · DOI
  43. Baltussen, 2009, Cost-effectiveness of selected interventions for hearing impairment in Africa and Asia: a mathematical modelling approach, Int J Audiol, 48, 144, 10.1080/14992020802538081 · DOI
  44. Baltussen, 2012, Cost effectiveness of strategies to combat vision and hearing loss in sub-Saharan Africa and South East Asia: mathematical modelling study, BMJ, 344, e615, 10.1136/bmj.e615 · DOI
  45. Bovier, 1999, A cost-effectiveness analysis of vaccination strategies against N. meningitidis meningitis in sub-Saharan African countries, Soc Sci Med, 48, 1205, 10.1016/S0277-9536(98)00419-5 · DOI
  46. Broughton, 2007, Economic evaluation of Haemophilus influenzae type B vaccination in Indonesia: a cost-effectiveness analysis, J Public Health (Oxf), 29, 441, 10.1093/pubmed/fdm055 · DOI
  47. Castaneda-Orjuela, 2011, Cost-effectiveness of the introduction of the pneumococcal polysaccharide vaccine in elderly Colombian population, Vaccine, 29, 7644, 10.1016/j.vaccine.2011.08.006 · DOI
  48. Castaneda-Orjuela, 2012, Cost-effectiveness of pneumococcal conjugate vaccines of 7, 10, and 13 valences in Colombian children, Vaccine, 30, 1936, 10.1016/j.vaccine.2012.01.031 · DOI
  49. de Soarez, 2011, Cost-effectiveness analysis of a universal infant immunization program with meningococcal C conjugate vaccine in Brazil, Value Health, 14, 1019, 10.1016/j.jval.2011.05.045 · DOI
  50. Duke, 2002, Haemophilus influenzae type b meningitis: how much better is prevention than cure?, P N G Med J, 45, 213
  51. Giglio, 2011, The pharmacoeconomics of pneumococcal conjugate vaccines in Latin America, Vaccine, 29, C35, 10.1016/j.vaccine.2011.06.095 · DOI
  52. Gupta, 2013, Cost-effectiveness of Haemophilus influenzae type b (Hib) vaccine introduction in the universal immunization schedule in Haryana State, India, Health Policy Plan, 28, 51, 10.1093/heapol/czs025 · DOI
  53. Hussey, 1995, The costs and benefits of a vaccination programme for Haemophilus influenzae type B disease, S Afr Med J, 85, 20
  54. LaForce, 2011, Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine, Health Aff (Millwood), 30, 1049, 10.1377/hlthaff.2011.0328 · DOI
  55. Lagos, 1998, The introduction of routine Haemophilus influenzae type b conjugate vaccine in Chile: a framework for evaluating new vaccines in newly industrializing countries, Pediatr Infect Dis J, 17, S139, 10.1097/00006454-199809001-00010 · DOI
  56. Limcangco, 2001, Cost-benefit analysis of a Haemophilus influenzae type B meningitis prevention programme in the Philippines, Pharmacoeconomics, 19, 391, 10.2165/00019053-200119040-00006 · DOI
  57. Moradi-Lakeh, 2005, Immunization against Haemophilus influenzae type B in Iran; cost-utility and cost-benefit analyses, Int J Prev Med, 3, 332
  58. Musgrove, 1992, Cost-benefit analysis of a regional system for vaccination against pneumonia, meningitis type B, and typhoid fever, Bull Pan Am Health Organ, 26, 173
  59. Somda, 2010, Modeling the cost-effectiveness of the integrated disease surveillance and response (IDSR) system: meningitis in Burkina Faso, PLoS One, 5, e13044, 10.1371/journal.pone.0013044 · DOI
  60. Stack, 2011, Estimated economic benefits during the ‘decade of vaccines’ include treatment savings, gains in labor productivity, Health Aff (Millwood), 30, 1021, 10.1377/hlthaff.2011.0382 · DOI
  61. Mangtani, 2005, An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting, Int J Epidemiol, 34, 565, 10.1093/ije/dyh341 · DOI
  62. Talbird, 2010, Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries, Vaccine, 28, G23, 10.1016/j.vaccine.2010.06.016 · DOI
  63. Dimitrov, 2003, Treatment of patients with bacterial infections of the central nervous system—a pharmaco-economical analysis, Boll Chim Farm, 142, 447
  64. Kim, 2010, Economic evaluation of pneumococcal conjugate vaccination in The Gambia, BMC Infect Dis, 10, 260, 10.1186/1471-2334-10-260 · DOI
  65. Graves, 2002, Cost data for individual patients included in clinical studies: no amount of statistical analysis can compensate for inadequate costing methods, Health Econ, 11, 735, 10.1002/hec.683 · DOI
  66. Augustovski, 2009, Childhood pneumococcal disease burden in Argentina, Rev Panam Salud Publica/Pan Am J Public Health, 25, 423, 10.1590/S1020-49892009000500007 · DOI
  67. Colombini, 2011, Costs and impact of meningitis epidemics for the public health system in Burkina Faso, Vaccine, 29, 5474, 10.1016/j.vaccine.2011.05.058 · DOI
  68. Colombini, 2009, Costs for households and community perception of meningitis epidemics in Burkina Faso, Clin Infect Dis, 49, 1520, 10.1086/644623 · DOI
  69. Griffiths, 2012, Costs of meningitis sequelae in children in Dakar, Senegal Pediatr Infect Dis J, 31, e189, 10.1097/INF.0b013e3182615297 · DOI
  70. Hussain, 2006, The cost of treatment for child pneumonias and meningitis in the Northern Areas of Pakistan, Int J Health Plann Manage, 21, 229, 10.1002/hpm.847 · DOI
  71. Lee, 2009, Economic evaluation of universal infant vaccination with 7vPCV in Hong Kong, Value Health, 12, S42, 10.1111/j.1524-4733.2009.00626.x · DOI
  72. Sinha, 2008, Cost-effectiveness of pneumococcal conjugate vaccination in Latin America and the Caribbean: a regional analysis, Rev Panam Salud Publica/Pan Am J Public Health, 24, 304, 10.1590/S1020-49892008001100002 · DOI
  73. Talbird, 2010, Residual economic burden of Streptococcus pneumoniae- and nontypeable Haemophilus influenzae-associated disease following vaccination with PCV-7: a multicountry analysis, Vaccine, 28, G14, 10.1016/j.vaccine.2010.06.080 · DOI
  74. Van Damme, 2004, Strengthening health services to control epidemics: empirical evidence from Guinea on its cost-effectiveness, Trop Med Int Health, 9, 281, 10.1046/j.1365-3156.2003.01189.x · DOI
  75. Akumu, 2007, Economic evaluation of delivering Haemophilus influenzae type b vaccine in routine immunization sevices in Kenya, Bull World Health Organ, 85, 511, 10.2471/BLT.06.034686 · DOI
  76. Nelson, 1995, Pediatric treatment costs and the HIV epidemic, Cent Afr J Med, 41, 139
  77. Gessner, 2008, Vaccine-preventable haemophilus influenza type B disease burden and cost-effectiveness of infant vaccination in Indonesia, Pediatr Infect Dis J, 27, 438, 10.1097/INF.0b013e318165f1ba · DOI
  78. Veeken, 1998, Priority during a meningitis epidemic: vaccination or treatment?, Bull World Health Organ, 76, 135
  79. Anh, 2010, Treatment costs of pneumonia, meningitis, sepsis, and other diseases among hospitalized children in Viet Nam, J Health Popul Nutr, 28, 436
  80. Levine, 1993, Cost-benefit analysis for the use of Haemophilus influenzae type b conjugate vaccine in Santiago, Chile, Am J Epidemiol, 137, 1221, 10.1093/oxfordjournals.aje.a116624 · DOI
  81. Sabayan, 2007, Viral infections, prevalence and costs: a 5-year, hospital based, retrospective observational study in Shiraz, Iran, Pak J Med Sci, 23, 580
  82. Platonov, 2006, Economic evaluation of Haemophilus influenzae type b vaccination in Moscow, Russian Federation, Vaccine, 24, 2367, 10.1016/j.vaccine.2005.11.054 · DOI
  83. Wright, 2007, Human immunodeficiency virus (HIV) related cryptococcal meningitis in rural central Thailand, Southeast Asian J Trop Med Public Health, 38, 58
  84. Griffiths, 2011, Comparative economic evaluation of Haemophilus influenzae type b vaccination in Belarus and Uzbekistan, PLoS One, 6, e21472, 10.1371/journal.pone.0021472 · DOI
  85. Constenla, 2007, Evaluating the costs of pneumococcal disease in selected Latin American countries, Rev Panam Salud Publica/Pan Am J Public Health, 22, 268, 10.1590/S1020-49892007000900007 · DOI

Cited by

Sorted by citations

Metadata

Authors
Portnoy, A., Jit, M., Lauer, J., Blommaert, A., Ozawa, S., Stack, M., Murray, J., & Hutubessy, R.
Affiliations
  • Johns Hopkins University (US)
  • Public Health England (GB)
  • World Health Organization (CH)
  • University of Antwerp (BE)
ORCID
Venue
Vaccine
Publisher
Elsevier BV
Published
2015-05
Volume
33
Pages
A240-A247
ISSN
0264-410X (ISSN-L)
DOI
10.1016/j.vaccine.2014.11.061
OpenAlex
W2091576298
Cited by
34
References
2
Citations by year
2025: 4 · 2024: 3 · 2023: 5 · 2022: 1 · 2021: 2 · 2020: 3 · 2019: 3 · 2018: 3 · 2017: 3 · 2016: 5 · 2015: 2
FWCI
0.53
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Vaccine (publishedVersion)
  • PubMed (publishedVersion)
  • Document Server@UHasselt (UHasselt) (submittedVersion)
Funders
World Health Organization
Topics
  • Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Epidemiology › Pneumonia and Respiratory Infections
Keywords
meningitis, cost of care, treatment costs, low- and middle-income countries, hospital costs, cost-effectiveness, bacterial meningitis, meningitis vaccine, sequelae, resource-limited settings
MeSH terms
Developing Countries, Humans, Meningitis, Models, Statistical, Health Care Costs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review